Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $482,591 - $594,967
7,452 Added 255.91%
10,364 $709,000
Q1 2024

May 14, 2024

BUY
$64.37 - $75.65 $187,445 - $220,292
2,912 New
2,912 $201,000
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $1.85 Million - $2.28 Million
35,581 Added 37.55%
130,342 $6.79 Million
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $493,232 - $599,421
9,022 Added 10.52%
94,761 $6 Million
Q1 2023

May 15, 2023

BUY
$43.8 - $56.99 $433,532 - $564,087
9,898 Added 13.05%
85,739 $4.64 Million
Q4 2022

Feb 14, 2023

BUY
$44.07 - $54.45 $285,793 - $353,108
6,485 Added 9.35%
75,841 $4.01 Million
Q3 2022

Nov 14, 2022

SELL
$42.7 - $59.99 $1.48 Million - $2.08 Million
-34,680 Reduced 33.33%
69,356 $3.23 Million
Q2 2022

Aug 15, 2022

SELL
$43.0 - $65.64 $3.13 Million - $4.78 Million
-72,765 Reduced 41.16%
104,036 $5.94 Million
Q1 2022

May 13, 2022

BUY
$38.74 - $62.09 $3.22 Million - $5.17 Million
83,201 Added 88.89%
176,801 $10.8 Million
Q4 2021

May 03, 2022

SELL
$35.2 - $53.42 $5.28 Million - $8.01 Million
-150,000 Reduced 61.58%
93,600 $4.9 Million
Q4 2021

Feb 14, 2022

BUY
$35.2 - $53.42 $5.18 Million - $7.86 Million
147,160 Added 152.59%
243,600 $12.8 Million
Q3 2021

Nov 15, 2021

BUY
$28.72 - $42.49 $247,652 - $366,391
8,623 Added 9.82%
96,440 $3.6 Million
Q2 2021

Aug 16, 2021

BUY
$29.3 - $44.5 $596,548 - $906,020
20,360 Added 30.18%
87,817 $3.59 Million
Q4 2020

Feb 16, 2021

SELL
$23.34 - $32.22 $1.18 Million - $1.63 Million
-50,634 Reduced 42.88%
67,457 $2.15 Million
Q3 2019

Nov 14, 2019

BUY
$7.47 - $14.03 $882,139 - $1.66 Million
118,091 New
118,091 $882,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $7.85B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.